Informations sur le produit
BTK IN-1 is a novel antibody drug conjugate (ADC) that targets the BTK protein and is being developed for the treatment of chronic lymphocytic leukemia. The BTK protein is expressed in cells of the microenvironment where cancerous cells are found, and when activated, it can lead to cancer cell proliferation. Clinical data has shown that BTK IN-1 reduces plasma concentrations of BTK, which might be an indication that this ADC is specific to the target. In addition, clinical development has been conducted on patients with lymphocytic leukemia or chronic lymphocytic leukemia. According to these clinical studies, BTK IN-1 appears to be an effective drug against cancerous cells in the blood and bone marrow.
Propriétés chimiques
Question d’ordre technique sur : 3D-VAC01440 BTK IN-1
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
